Magovcevic-Liebisch Ivana 4

What Happened Ivana Magovcevic-Liebisch, a director of Acrivon Therapeutics (ACRV), was granted a derivative equity award covering 20,275 shares on 2026-06-17. The filing reports the award at a reported price of $0.00 and a total reported value of $0 (derivative award). This was a grant of an option/award (transaction code A), not a market purchase or sale.

Key Details

• Transaction date: 2026-06-17 (reported on Form 4 filed 2026-06-22).
• Transaction type/code: Award/Grant (A) — derivative equity award.
• Shares/units: 20,275 shares (derivative). Reported price: $0.00; reported value: $0.
• Vesting: Per footnote, the shares subject to the option vest on the date immediately preceding the issuer's next annual meeting of stockholders, subject to the reporting person's continuous service.
• Shares owned after transaction: Not specified in the information provided in your summary.
• Timeliness: The Form 4 was filed five days after the transaction (6/22 vs 6/17); Form 4s are generally due within two business days, so this filing appears to have been submitted after that typical window.

Context This was a derivative equity grant (an option/award) that vests on a near-term schedule; it does not represent an immediate cash purchase or sale of shares. Such awards are commonly used for director compensation and do not by themselves indicate immediate buying or selling in the market.